Compare Cytokinetics Inc (CYTK) vs Dominion Energy Inc (D) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Dominion Energy Inc — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while Dominion Energy Inc trades at $67.66 (market cap $59.06B). The key difference: Dominion Energy Inc is far larger — about 5.5× Cytokinetics Inc's market cap, and Dominion Energy Inc pays a 3.98% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | D | |
|---|---|---|
Market Cap | $10.78B | $59.06B |
Sector | Technology | Utilities |
52-Week High | $87.26 | $71.67 |
52-Week Low | $34.31 | $57.08 |
Enterprise Value | $10.88B | $113.18B |
Dividend Yield | — | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Dominion Energy (D) trades at $67.39, up 0.88% today, with a bearish technical signal but strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.79, exceeding expectations, and maintains a stable dividend. Revenue growth is robust, rising to $16.51B in 2025, with a net income margin of 13.99%. Analyst consensus is mixed, with a $70.43 price target, but technical indicators show resistance near $68.
Outlook remains cautious due to high debt levels and bearish technicals, though fundamentals are solid with consistent profitability. Risks include regulatory pressures and capital expenditure demands. The stock offers income appeal with dividends, but near-term price action may face headwinds from technical selling pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →
